High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia : A community-based cohort study
(2025) In International Journal of Cancer 156(10). p.1995-2009- Abstract
High-risk human papillomavirus (hrHPV) genotype is needed for adequate cervical cancer screening and HPV vaccination program evaluation as recommended by different guidelines. We aimed to assess the rate of HPV infection and HPV genotype distribution using vaginal self-sampling in a cohort of unscreened reproductive-age women in Ethiopia. A community-based cohort study was conducted with women aged 23–46 living in Adama, Ethiopia. A total of 885 self-collected vaginal swabs were obtained and tested for hrHPV genotypes with the real-time polymerase chain reaction technique. The overall hrHPV prevalence was 21.1% (187/885, 95% confidence interval [CI]: 18.5–24.0). Among women living with human immunodeficiency virus, 46% (30/56) (95% CI:... (More)
High-risk human papillomavirus (hrHPV) genotype is needed for adequate cervical cancer screening and HPV vaccination program evaluation as recommended by different guidelines. We aimed to assess the rate of HPV infection and HPV genotype distribution using vaginal self-sampling in a cohort of unscreened reproductive-age women in Ethiopia. A community-based cohort study was conducted with women aged 23–46 living in Adama, Ethiopia. A total of 885 self-collected vaginal swabs were obtained and tested for hrHPV genotypes with the real-time polymerase chain reaction technique. The overall hrHPV prevalence was 21.1% (187/885, 95% confidence interval [CI]: 18.5–24.0). Among women living with human immunodeficiency virus, 46% (30/56) (95% CI: 33.7–59) were hrHPV positive compared with 19% (157/820) (95% CI: 16.2–22) of human immunodeficiency virus-negative women. The most frequent genotypes were HPV16 (3.1%), HPV51 (3.1%), HPV35 (2.6%), HPV56 (2.6%), HPV52 (2.4%), HPV31 (2.5%), and HPV39 (2.5%). Among the 187 HPV-positive women in self-samples, HPV 16/18 was found in 21% (39), HPV 16/18/45 was found in 24% (44), and HPV 16/18/31/33/45/52/58 was prevalent in 56% (104). Out of 116 biopsies, 7% (8) had cervical intraepithelial lesions and worse identified. Of these eight cervical intraepithelial lesions and worse patients, only 25% tested positive for HPV-16; none tested positive for HPV-18 or 45. One out of five women tested positive for hrHPV genotypes. Other HPV genotypes not covered by the quadrivalent HPV vaccine but associated with clinically significant cervical high-grade lesions or cancer were detected in 75%. It is more effective to prevent cervical cancer by switching to the nine-valent HPV vaccine.
(Less)
- author
- Kebede, Habtamu Biazin LU ; Mekuria, Selamawit LU ; Asegid, Nahom ; Forslund, Ola LU ; Borgfeldt, Christer LU ; Jerkeman, Mats LU ; Mihret, Adane and Abebe, Tamrat
- organization
- publishing date
- 2025-05
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- cervical cancer, Ethiopia, genotyping, human papillomavirus, screening, self-sampling
- in
- International Journal of Cancer
- volume
- 156
- issue
- 10
- pages
- 15 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:39950735
- scopus:85219730990
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.35335
- language
- English
- LU publication?
- yes
- id
- 9b4a8e4a-76c9-4679-95a1-01f4a8100a5a
- date added to LUP
- 2025-06-25 12:17:01
- date last changed
- 2025-07-09 14:28:34
@article{9b4a8e4a-76c9-4679-95a1-01f4a8100a5a,
abstract = {{<p>High-risk human papillomavirus (hrHPV) genotype is needed for adequate cervical cancer screening and HPV vaccination program evaluation as recommended by different guidelines. We aimed to assess the rate of HPV infection and HPV genotype distribution using vaginal self-sampling in a cohort of unscreened reproductive-age women in Ethiopia. A community-based cohort study was conducted with women aged 23–46 living in Adama, Ethiopia. A total of 885 self-collected vaginal swabs were obtained and tested for hrHPV genotypes with the real-time polymerase chain reaction technique. The overall hrHPV prevalence was 21.1% (187/885, 95% confidence interval [CI]: 18.5–24.0). Among women living with human immunodeficiency virus, 46% (30/56) (95% CI: 33.7–59) were hrHPV positive compared with 19% (157/820) (95% CI: 16.2–22) of human immunodeficiency virus-negative women. The most frequent genotypes were HPV16 (3.1%), HPV51 (3.1%), HPV35 (2.6%), HPV56 (2.6%), HPV52 (2.4%), HPV31 (2.5%), and HPV39 (2.5%). Among the 187 HPV-positive women in self-samples, HPV 16/18 was found in 21% (39), HPV 16/18/45 was found in 24% (44), and HPV 16/18/31/33/45/52/58 was prevalent in 56% (104). Out of 116 biopsies, 7% (8) had cervical intraepithelial lesions and worse identified. Of these eight cervical intraepithelial lesions and worse patients, only 25% tested positive for HPV-16; none tested positive for HPV-18 or 45. One out of five women tested positive for hrHPV genotypes. Other HPV genotypes not covered by the quadrivalent HPV vaccine but associated with clinically significant cervical high-grade lesions or cancer were detected in 75%. It is more effective to prevent cervical cancer by switching to the nine-valent HPV vaccine.</p>}},
author = {{Kebede, Habtamu Biazin and Mekuria, Selamawit and Asegid, Nahom and Forslund, Ola and Borgfeldt, Christer and Jerkeman, Mats and Mihret, Adane and Abebe, Tamrat}},
issn = {{0020-7136}},
keywords = {{cervical cancer; Ethiopia; genotyping; human papillomavirus; screening; self-sampling}},
language = {{eng}},
number = {{10}},
pages = {{1995--2009}},
publisher = {{John Wiley & Sons Inc.}},
series = {{International Journal of Cancer}},
title = {{High-risk human papillomavirus genotypes in previously unscreened reproductive-age women in Ethiopia : A community-based cohort study}},
url = {{http://dx.doi.org/10.1002/ijc.35335}},
doi = {{10.1002/ijc.35335}},
volume = {{156}},
year = {{2025}},
}